Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02374957 · ClinicalTrials.gov registry record · Phase 4
Cilostazol After Lower Extremity Arterial Revascularization Trial
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT02374957 is a Phase 4 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT02374957, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Twenty patients will be recruited to CLEAR. Ten will be randomized to the treatment arm (Cilostazol) and tenwill be randomized to the control group. Patients randomized to the treatment arm will receive Cilostazol for 90 days. The primary purpose of this study is to collect quality of life data on patients undergoing peripheral revascularization in order to determine the sample size required to adequately power a trial of Cilostazol versus usual care without Cilostazol and its effect on quality of life.
Interventions
- DRUG Cilostazol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02374957
The ClinicalTrials.gov registry entry for NCT02374957 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cilostazol is the first listed.
NCT02374957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02374957 about?
NCT02374957 is a clinical study titled "Cilostazol After Lower Extremity Arterial Revascularization Trial". Twenty patients will be recruited to CLEAR. Ten will be randomized to the treatment arm (Cilostazol) and tenwill be randomized to the control group. Patients randomized to the treatment arm will receive Cilostazol for 90 days. The primary purpose of this study is to collect quality of life data on p...
What is the current status of trial NCT02374957?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2015-02. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT02374957?
The interventions under investigation include: Cilostazol (DRUG).
Who is sponsoring clinical trial NCT02374957?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.